EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 3.0

Screening for medium-chain acyl CoA dehydrogenase deficiency: current perspectives

Can Ficicioglu, Claudia Soler-Alfonso, Michael Bennett

Research and Reports in Neonatology · 2016-01 · 1

DOI: 10.2147/rrn.s60617 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Research and Reports in Neonatology, 2016-01. Verfasst von Can Ficicioglu und 2 weiteren Autor:innen. Die Arbeit wurde bisher 3-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Medium-chain acyl-CoA dehydrogenase (MCAD) deficiency is the most common disorder associated with fatty acid oxidation. The disorder is characterized by inability to generate sufficient energy from fatty acid metabolism during periods of catabolic stress caused by intercurrent illness or prolonged fasting. The metabolic consequences are severe and include hypoketotic hypoglycemia leading to a Reye-like hepatic encephalopathy syndrome and sudden death. If individuals are detected before a life-threatening episode, the complications of MCAD deficiency are preventable. Newborn metabolic screening enables the early detection of MCAD deficiency in many countries worldwide. The metabolic marker for MCAD deficiency “octanoylcarnitine” (C8) can be detected with a high degree of sensitivity in the newborns by tandem mass spectrometry. The 985A>G (K329E) mutation accounts for the majority of disease alleles, and approximately 47%–80% of MCAD patients are homozygotes for this mutation. Newborns homozygous for the 985A>G mutation have higher octanoylcarnitine levels than those who are heterozygous for 985A>G mutation or possess other genotypes. Time of sampling after birth and prematurity may affect the octanoylcarnitine levels in MCAD-deficient newborns. Tandem mass spectrometry newborn blood spot screening for MCAD deficiency is accurate and effective, and reduces morbidity and mortality in affected children. Keywords: MCAD, newborn screening, C8, octanoylcarnitine, tandem mass spectrometry, sudden death in childhood

Zitieren

APA

Ficicioglu, C., Soler-Alfonso, C., & Bennett, M. (2016). Screening for medium-chain acyl CoA dehydrogenase deficiency: current perspectives. Research and Reports in Neonatology, 1. https://doi.org/10.2147/rrn.s60617

Vancouver

Ficicioglu C, Soler-Alfonso C, Bennett M. Screening for medium-chain acyl CoA dehydrogenase deficiency: current perspectives. Research and Reports in Neonatology. 2016:1. doi:10.2147/rrn.s60617

BibTeX
@article{Ficicioglu2016,
  author = {Ficicioglu, Can and Soler-Alfonso, Claudia and Bennett, Michael},
  title = {Screening for medium-chain acyl CoA dehydrogenase deficiency: current perspectives},
  journal = {Research and Reports in Neonatology},
  year = {2016},
  pages = {1},
  doi = {10.2147/rrn.s60617}
}
Kostenlos starten →